Abstract Despite improvements in survival, cancer remains the leading cause of non-accidental death in children and adolescents, who risk receiving high-intensity end-of-life (HI-EOL) care. Objective To analyse treatments for relapses (particularly in the last weeks of life), assess their impact on the EOL, identify patients most likely to receive HI-EOL care and examine whether palliative care services can contain the intensity of EOL care. Methods This retrospective study involved patients treated at the paediatric oncology unit of the Istituto Nazionale Tumori in Milan who died between 2018 and 2020. The primary outcome was HI-EOL care, defined as: ≥1 session of intravenous chemotherapy <14 days before death; ≥1 hospitalisation in intensive care in the last 30 days of life and ≥1 emergency room admission in the last 30 days of life. Results The study concerned 68 patients, and 17 had HI-EOL care. Patients given specific in-hospital treatments in the last 14 days of their life more frequently died in hospital. Those given aggressive EOL care were less likely to die at home or in the hospice. Patients with central nervous system (CNS) tumours were more likely to have treatments requiring hospitalisation, and to receive HI-EOL care. Conclusion These results underscore the importance of considering specific treatments at the EOL with caution. Treatments should be administered at home whenever possible. The early activation of palliative care, especially for fragile and complicated patients like those with CNS cancers, could help families cope with the many problems they face.

Children and adolescent solid tumours and high-intensity end-of-life care : what can be done to reduce acute care admissions? / M.G. Podda, E. Schiavello, C.A. Clerici, R. Luksch, M. Terenziani, A. Ferrari, M. Casanova, F. Spreafico, C. Meazza, V. Biassoni, S. Chiaravalli, N. Puma, L. Bergamaschi, G. Gattuso, G. Sironi, O. Nigro, M. Massimino. - In: BMJ SUPPORTIVE & PALLIATIVE CARE. - ISSN 2045-435X. - (2021 Sep 07). [Epub ahead of print] [10.1136/bmjspcare-2021-003031]

Children and adolescent solid tumours and high-intensity end-of-life care : what can be done to reduce acute care admissions?

E. Schiavello
Secondo
;
C.A. Clerici;M. Terenziani;A. Ferrari;V. Biassoni;G. Sironi;
2021

Abstract

Abstract Despite improvements in survival, cancer remains the leading cause of non-accidental death in children and adolescents, who risk receiving high-intensity end-of-life (HI-EOL) care. Objective To analyse treatments for relapses (particularly in the last weeks of life), assess their impact on the EOL, identify patients most likely to receive HI-EOL care and examine whether palliative care services can contain the intensity of EOL care. Methods This retrospective study involved patients treated at the paediatric oncology unit of the Istituto Nazionale Tumori in Milan who died between 2018 and 2020. The primary outcome was HI-EOL care, defined as: ≥1 session of intravenous chemotherapy <14 days before death; ≥1 hospitalisation in intensive care in the last 30 days of life and ≥1 emergency room admission in the last 30 days of life. Results The study concerned 68 patients, and 17 had HI-EOL care. Patients given specific in-hospital treatments in the last 14 days of their life more frequently died in hospital. Those given aggressive EOL care were less likely to die at home or in the hospice. Patients with central nervous system (CNS) tumours were more likely to have treatments requiring hospitalisation, and to receive HI-EOL care. Conclusion These results underscore the importance of considering specific treatments at the EOL with caution. Treatments should be administered at home whenever possible. The early activation of palliative care, especially for fragile and complicated patients like those with CNS cancers, could help families cope with the many problems they face.
brain; paediatrics; quality of life; supportive care; terminal care
Settore M-PSI/08 - Psicologia Clinica
7-set-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
bmjspcare-2021-003031.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 277.11 kB
Formato Adobe PDF
277.11 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/879812
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact